






Claims

1. A method of inhibiting fungal growth in a host comprising administering to [said host an acceptable carrier and an effective amount of a compound] a host infected with a fungi, a composition comprising an acceptable carrier and a compound selected from the group consisting of formulae 1a, 1b, 1c, 1d and 1e, for a time and under conditions effective to inhibit fungal growth wherein the structures of said formulae are as follows:





1d, Dov-Val-Dil-Dap-Phe-OMe





1e, Dov-Val-Dil-Dap-Met-3-quinolylamide


2. The method according to claim 1 in which said [fungi are] fungal growth is
Cryptococcus neoformans.
3. The method according to claim 1 in which said [fungi induced infections]
fungal growth are cryptococcosis and epidermal and systemic infections
resulting from contact with *Cryptococcus neoformans*.
4. The method according to claim 9 in which said active ingredient is
administered to said host by parenteral means.

5. The method according to claim 9 in which said active ingredient is administered topically to said host.
- 5 6. The method according to claim 9 in which said active ingredient is administered intravenously to said host.
7. The method according to claim 9 in which said active ingredient is administered in a suppository inserted in said host.
- 10 8. The method according to claim 5 [in which] wherein said carrier [comprises] said carrier is selected from the group consisting of a water-and-oil emulsion, petrolatum, mineral oil, a moisturizer, [a solubilizer and fragrance] and a solubilizer.
- 15 9. The method according to claim 3 wherein said host is a mammal.
10. The method according to claim 9 in which said mammal is a human.
11. The method according to claim 10 in which said active ingredient is
20 administered to said host by parenteral means.
12. The method according to claim 10 in which said active ingredient is administered topically to said host.
- 25 13. The method according to claim 10 in which said active ingredient is administered intravenously to said host.
14. The method according to claim 10 in which said active ingredient is

administered in a suppository inserted in said host.


15. The method according to claim 12 [in which] wherein said carrier
5 [comprises] said carrier is selected from the group consisting of a water-
and-oil emulsion, petrolatum, mineral oil, a moisturizer, [a solubilizer and
fragrance] and a solubilizer.
- 10 16. A method of inhibiting growth of a fungus in a host that is infected with a
fungus comprising administering to said host a composition comprising an
acceptable carrier, and a compound selected from the group consisting of
formulae 1a, 1b, 1c, 1d, and 1e, wherein said method, said composition is
administered to the host for a time and under conditions effective to inhibit
said fungal growth; and wherein the structures of said formulae are as
15 follows:






5

1c, Dov-Val-Dil-Dap-Phe-3-[(5-thiomethyl)-1,4-thiadiazolamide]



10

1d, Dov-Val-Dil-Dap-Phe-OMe



15

1e, Dov-Val-Dil-Dap-Met-3-quinolylamide

20

17. The method of claim 8 in which said carrier contains a fragrance.

18. The method of claim 15 in which said carrier contains a fragrance.